Novo and Lilly gain as weight loss pills reach new users
Early data for weight-loss pills from Novo Nordisk and Eli Lilly suggest the drugs are reaching new patients. This expansion helps firms counter pricing pressure.
Xurve View
Insights:
Xurve View
NOVO NORDISK A/S-B and ELI LILLY & CO shares rose after early data showed oral weight-loss pills are expanding the obesity market. Wegovy pill sales in the first quarter doubled analyst expectations, while Lilly raised its annual profit forecast the previous week. Oral treatments reach needle-phobic patients, potentially unlocking a market of 100 million obese adults in the United States.
